Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA For Emergency Use - the First Single-Shot Vaccine in Fight Against Global Pandemic.<br /><br />Data demonstrated protection against COVID-19 related hospitalization and death, across countries with different variants. Shipping vaccine immediately, delivering more than 20 million doses to U.S. in March, 100 million doses in first half of 2021.<br /><br />The company announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older.<br /><br />This decision was based on the totality of scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease across all regions studied, and showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination.<br /><br />This article was originally published by Johnson & Johnson press release on February 27, 2021.<br />http://bit.ly/2Mxwgge<br /><br />FIND the model and photographer created this video on Pexels:<br />https://bit.ly/3bR4F28<br /><br />SUBSCRIBE to our channel:<br />http://bit.ly/3pOwYUZ
